AFROEU

What Is Careprost and What Is It Used For?

What It Is: Careprost is a bimatoprost 0.03% ophthalmic (eye) solution. Bimatoprost is a prostaglandin analog — a synthetic compound that mimics naturally occurring substances in the body that affect fluid drainage and tissue growth.

Two Main Uses

• Glaucoma and high eye pressure (ocular hypertension): Bimatoprost 0.03% is FDA-approved to lower elevated pressure inside the eye in patients with open-angle glaucoma or ocular hypertension. It works by increasing the outflow of aqueous humor (the fluid inside the eye), which reduces pressure.
• Eyelash growth (hypotrichosis): Bimatoprost 0.03% is also FDA-approved to treat hypotrichosis of the eyelashes — a condition where eyelashes are thin, short, or sparse. It increases eyelash length, thickness, and darkness.

How Each Use Is Applied

• Glaucoma: Bimatoprost ophthalmic solution 0.03% (Lumigan) is FDA-approved for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension: 1 drop placed in the affected eye(s) once daily in the evening.
• Eyelash growth: Bimatoprost ophthalmic solution 0.03% (Latisse) is FDA-approved for the treatment of hypotrichosis of the eyelashes. Apply nightly directly to the skin of the upper eyelid margin at the base of the eyelashes using the accompanying sterile, single-use applicators. Any excess solution outside the upper eyelid margin should be blotted with a tissue or other absorbent cloth to prevent hyperpigmentation or unwanted hair growth on adjacent skin.

Note: Careprost is not an FDA-approved brand name in the United States; it is a product manufactured by Sun Pharmaceutical Industries Ltd. and should not be substituted for FDA-approved bimatoprost products without medical guidance.

Note: Patients using bimatoprost for glaucoma may notice eyelash changes — including increased length, thickness, and number of lashes — as a side effect of treatment.

How Does Careprost Work?

Mechanism for Eyelash Growth

Bimatoprost is a structural prostaglandin analog — a compound similar in structure to naturally occurring prostaglandins (hormone-like substances in the body).

• The exact process is not fully understood.
• It is believed to work by increasing the percentage of hairs in the growth phase (called the anagen phase) and extending how long that phase lasts.
• The result: lashes grow longer, fuller, and darker over time.

Note: The precise mechanism by which bimatoprost promotes eyelash growth has not been completely established by researchers.

Mechanism for Glaucoma

Bimatoprost lowers pressure inside the eye (intraocular pressure, or IOP) by helping fluid drain out more efficiently. It does not reduce how much fluid the eye produces.

• Trabecular meshwork (conventional pathway): Increases aqueous humor outflow through this route; Bimatoprost (a prostamide, pharmacologically distinct from traditional prostaglandins) is unique among hypotensive lipids for significantly enhancing trabecular outflow alongside its primary uveoscleral mechanism.
• Uveoscleral pathway (pressure-insensitive pathway): Increases fluid drainage through this route as its primary mechanism by relaxing the ciliary muscle (a small muscle inside the eye). Together, these dual-pathway effects produce a mean IOP reduction of approximately 7–8 mmHg (roughly 33% from baseline) in clinical trials of Bimatoprost 0.03%, reflecting total pressure reduction rather than a percentage increase in any single drainage pathway.

Bimatoprost also triggers the production of enzymes called matrix metalloproteinases (MMP-1, MMP-3, and MMP-9). These enzymes break down and remodel tissue in the eye, further reducing resistance to fluid outflow.

How to Apply Careprost: Step-by-Step Instructions

Important Safety Warning: Careprost (bimatoprost) solution contains benzalkonium chloride, which can be absorbed by soft contact lenses. Always remove contact lenses before applying. Wait 15 minutes after application before putting them back in.

Applying Latisse for Eyelash Growth

Follow these steps once every night:

Important: Latisse (bimatoprost ophthalmic solution 0.03%) is the only FDA-approved medication for the treatment of hypotrichosis of the eyelashes. Products such as Careprost are unapproved drugs in the United States and do not have FDA-verified labeling for safety, efficacy, or manufacturing standards. Use only FDA-approved Latisse, obtained through a licensed healthcare provider, for eyelash growth treatment.

1. Wash your face and remove all makeup. Take out any contact lenses.
2. Place 1 drop of bimatoprost ophthalmic solution 0.03% onto the sterile disposable applicator brush included in the package.
3. Draw the brush evenly along the skin of the upper eyelid margin — right at the base of the upper lashes. The area should feel lightly moist, with no runoff.
4. Blot any excess solution outside the upper lash line with a tissue or absorbent cloth.
5. Discard the applicator. Use a fresh sterile applicator for the other eye.
6. Wait 15 minutes, then reinsert contact lenses if needed.

Note: Do NOT apply to the lower eyelash line. Do not reuse applicators or substitute any other brush. Do not let the bottle tip touch any surface — this prevents contamination.

When Will You See Results? Careprost Timeline

Note: Results with bimatoprost are gradual. Most patients do not see significant improvement until around 2 months of consistent use.

What the Clinical Evidence Shows

• By 8 weeks: Statistically significant improvements in eyelash prominence were first recorded in clinical studies.
• By 12–16 weeks: Continued, measurable improvements in lash appearance were confirmed at both the 12-week and 16-week marks.
• 50% of patients in a clinical study saw significant improvement by the 2-month point.

Important: Results build slowly. Skipping applications can delay progress. Talk to your doctor if you have questions about your individual timeline.

Side Effects and Safety Information

Important Safety Warning: Bimatoprost may permanently change the color of your iris (the colored part of your eye). Brown pigmentation can spread from the pupil outward. This change may not appear for several months to years — and is likely irreversible. Talk to your doctor before starting treatment.

Common Side Effects

These reactions generally occurred in ≥1% to ≥10% of patients in clinical studies, depending on the specific medication and its clinical trial data. Per FDA labeling requirements (21 CFR 201.57(c)(7)), the 'Adverse Reactions' section must list all adverse reactions identified during clinical trials that are reasonably associated with the use of the drug. While FDA Guidance for Industry suggests a frequency of 5% or more as a typical threshold for inclusion in the 'Common Adverse Reactions' subsection, this is a presentation guideline rather than a codified regulatory definition of the term "common" itself. For reference, the Council for International Organizations of Medical Sciences (CIOMS) defines "common" (frequent) as occurring in 1%–10% of patients, and "very common" as occurring in more than 10%. Consult the prescribing information for the specific drug for exact frequency data.

• Eye itching (pruritus)
• Eye redness (conjunctival hyperemia)
• Skin darkening around the eye area
• Eye irritation
• Dry eye symptoms
• Redness of the eyelid skin (periorbital erythema)
• Gradual changes to eyelashes — increased length, thickness, and number (usually reversible when treatment stops)
• Unwanted hair growth in areas where the solution repeatedly contacts skin

Rare but Important Risks

• Permanent iris color change: Increased brown pigmentation of the iris is likely permanent.
• Eyelid and lash darkening: Expected to increase during use; usually reversible after stopping in most patients.
• Macular edema (swelling in the back of the eye): Reported during bimatoprost use. Higher risk in certain patients with lens conditions or known eye inflammation.
• Worsening eye inflammation: Use with caution if you have active intraocular inflammation (e.g., uveitis).
• Allergy: Do not use if you are allergic to bimatoprost or any ingredient in the solution.

Precautions, Contraindications, and Drug Interactions

Important Safety Warning: Do not use bimatoprost if you have a known allergy to bimatoprost or any ingredient in the solution. Talk to your doctor before use if you are pregnant, planning to become pregnant, or breastfeeding.

Who Should Not Use Bimatoprost

• Allergy to bimatoprost: Do not use if you are allergic to bimatoprost or any component of the eye drops.
• Pregnancy: There are no adequate, well-controlled studies in pregnant women. Use only if your doctor decides the potential benefit outweighs the potential risk to the baby.
• Children under 16: Not recommended for patients below age 16. Long-term use may cause increased pigmentation (darkening of skin or eye color), and safety in this age group has not been established.

Always talk to a licensed healthcare provider before starting bimatoprost to make sure it is safe for you.

Careprost vs. Latisse: What Is the Difference?

Latisse (bimatoprost ophthalmic solution 0.03%) and Careprost are two brands that contain the same active pharmaceutical ingredient (API), bimatoprost, at a concentration of 0.03%. Latisse is FDA-approved (NDA 022341) for the treatment of hypotrichosis of the eyelashes, indicated to increase eyelash length, thickness, and darkness. Careprost, manufactured by Sun Pharmaceutical Industries Ltd., is primarily marketed in India and is not FDA-approved for sale in the United States; products imported outside of regulated channels may be considered unapproved or counterfeit under US regulatory standards, posing potential safety risks to consumers. Despite sharing the same API and concentration, patients in the US should be counseled that only Latisse carries FDA approval for this indication. Common side effects associated with bimatoprost 0.03% include eye pruritus, conjunctival hyperemia, and skin hyperpigmentation, and these risks apply regardless of which brand is used.

Frequently Asked Questions